Table IV.

Univariate and multivariate analysis of prognostic factors for overall survival.

	Univariate		Multivariate
Prognostic factor	HR (95%CI)	P-value	HR (95%CI)	P-value
MUC1 (≥0.056 vs. <0.056, ratio to GAPDH)	2.233 (1.214-4.485)	0.011	2.364 (1.127-4.960)	0.023
CEA (≥20 ng/ml vs. <20 ng/ml)	2.197 (1.106-4.365)	0.025	2.315 (1.081-4.958)	0.031
CA-19-9 (≥37 ng/ml vs. <37 ng/ml)	2.675 (1.368-5.231)	0.004	2.303 (1.109-4.780)	0.025
Differentiation (poor vs. well)	2.284 (1.102-4.736)	0.026	1.102 (0.485-2.502)	0.816
Tumor diameter (>5 cm vs. ≤5 cm)	2.236 (1.110-4.503)	0.024	1.461 (1.127-4.960)	0.320
LN metastasis (yes vs. no)	4.440 (1.916-10.288)	0.001	2.846 (1.259-6.436)	0.012
T stage (T2-4 vs. T1)	1.435 (0.995-2.070)	0.053
Surrounding tissue invasion (yes vs. no)	2.612 (0.797-8.557)	0.113
Tumor number (solitary vs. multiple)	1.603 (0.838-3.064)	0.154
Nerve invasion (yes vs. no)	1.117 (0.268-4.645)	0.879
Vascular invasion (yes vs. no)	0.798 (0.378-1.681)	0.552
Bile duct invasion (presence vs. absence)	1.995 (0.762-5.018)	0.163

LN, lymph node; HR, hazard ratio; CA, cancer antigen.